Roth Capital Forecasts Higher Earnings for LeMaitre Vascular

Key Points

• Roth Capital has raised its Q2 2026 EPS estimate for LeMaitre Vascular from $0.62 to $0.63, indicating positive expectations for the company’s earnings performance.
• LeMaitre Vascular's quarterly earnings report revealed an EPS of $0.60, surpassing the consensus estimate of $0.57, alongside a revenue increase of 15% year-over-year.
• The company will distribute a quarterly dividend of $0.20 per share on September 4th, reflecting a dividend yield of 0.8% and a payout ratio of 40.40%.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) - Research analysts at Roth Capital boosted their Q2 2026 earnings per share estimates for shares of LeMaitre Vascular in a report released on Tuesday, August 5th. Roth Capital analyst J. Wittes now anticipates that the medical instruments supplier will post earnings of $0.63 per share for the quarter, up from their previous forecast of $0.62. The consensus estimate for LeMaitre Vascular's current full-year earnings is $1.94 per share. Roth Capital also issued estimates for LeMaitre Vascular's Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.64 EPS, FY2026 earnings at $2.49 EPS and FY2027 earnings at $2.96 EPS.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. The business had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The business's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 EPS.

Several other research analysts have also recently weighed in on the company. Barrington Research upgraded LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a report on Wednesday. Cantor Fitzgerald boosted their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of "Hold" and an average target price of $98.00.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock traded down $1.98 on Thursday, hitting $92.28. 149,596 shares of the company were exchanged, compared to its average volume of 146,164. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of 44.80, a price-to-earnings-growth ratio of 2.42 and a beta of 0.79. The company has a 50-day moving average price of $83.35 and a 200 day moving average price of $86.65. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $109.58. The company has a quick ratio of 13.83, a current ratio of 13.96 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a $0.20 dividend. The ex-dividend date is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular's dividend payout ratio is currently 38.83%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 100,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the transaction, the chief executive officer directly owned 1,727,003 shares in the company, valued at approximately $161,492,050.53. This represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 200,000 shares of company stock valued at $17,907,857 in the last 90 days. Corporate insiders own 9.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust lifted its holdings in LeMaitre Vascular by 1,913.3% in the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 287 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in LeMaitre Vascular in the first quarter valued at approximately $26,000. NBC Securities Inc. purchased a new stake in LeMaitre Vascular in the first quarter valued at approximately $36,000. Geneos Wealth Management Inc. raised its position in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after purchasing an additional 398 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in LeMaitre Vascular in the first quarter valued at approximately $50,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.